Robert Wessman will speak on “The strategy and competitiveness of Actavis in a fiercely competitive environment” in London on Wednesday.
Actavis generic pharmaceuticals have announced that its President & CEO, Robert Wessman, will discuss “The strategy and competitiveness of Actavis in a fiercely competitive environment” at the annual UBS Global Specialty and Generic Pharmaceuticals Conference on 28th May 2008.
The conference, held in London for the first time in its twelve year history, features presentations from over 80 top executives of leading specialty and generic pharmaceutical companies from North America, Europe, Africa, Latin America and Asia-Pacific, as well as panel discussions focused on key sector trends and issues.
Actavis is an Iceland-based generic pharmaceuticals company which specialises in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries and over 11,000 employees.